However, the lack of changes in Th1 cells or IFN-γ in the blood of patients with PBC and the ineffectiveness of ustekinumab, which neutralizes IL-12/23 p40, as reflected in clinical trials for PBC, suggest that Th1 cells may contribute a little to the pathology [67]. This evidence concerns the gene IL9 and primary biliary cholangitis.